Salivary Angiotensin-Converting Enzyme and Periodontal Disease in Cardiovascular Disease (NCT07721428) | Clinical Trial Compass
CompletedNot Applicable
Salivary Angiotensin-Converting Enzyme and Periodontal Disease in Cardiovascular Disease
Turkey (Türkiye)76 participantsStarted 2021-03-01
Plain-language summary
The goal of this observational study is to learn whether the renin-angiotensin system, measured by angiotensin-converting enzyme (ACE) and angiotensin-converting enzyme 2 (ACE2) in saliva and blood, is associated with periodontal disease severity in adults undergoing cardiovascular evaluation.
The main questions it aims to answer are:
* Are salivary and blood ACE and ACE2 levels different according to periodontal disease severity?
* Do salivary ACE and ACE2 levels reflect the corresponding blood levels?
* Are ACE and ACE2 levels related to clinical measures of periodontal disease?
Participants will:
* Complete medical and dental history assessments.
* Undergo a comprehensive periodontal examination, including measurements of plaque, gingival inflammation, bleeding on probing, probing pocket depth, clinical attachment loss, and the number of remaining teeth.
* Provide saliva and blood samples for laboratory measurement of ACE and ACE2.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18 years or older.
* Having at least 20 natural teeth.
* Diagnosis of cardiovascular disease confirmed by coronary angiography.
* Ability and willingness to provide written informed consent.
Exclusion Criteria:
* Fewer than 20 natural teeth.
* Pregnancy or lactation.
* Periodontal treatment within the previous 6 months.
* Antibiotic or anti-inflammatory drug use within the previous 3 months.
* Presence of systemic inflammatory, autoimmune, or infectious diseases that could affect periodontal inflammation.
* History of malignancy.
* Requirement for antibiotic prophylaxis before periodontal examination.
* Refusal or inability to provide saliva or blood samples.
* Having a history of COVID-19 infection where less than 2 months had elapsed since the last positive RT-PCR test result
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.